Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Nom du journal : Ann Oncol
Année : 2023
Volume : 34
Page de départ : 468-476
